Abstract 4382
Background
Implementing screening programs for risk populations can reduce lung cancer mortality by detecting the disease at early stages, when surgical intervention or chemotherapy treatment can be conducted with best prognosis. Screening protocols based on Low-Dose CT presents a series of drawbacks and needs complementary methods for improving sensitivity and specificity in the screening procedure. Thermal Liquid Biopsy (TLB) is as a complementary technique that, combined with imaging techniques, may improve the efficacy of the screening method.
Methods
Blood samples from Healthy Controls (HC) and Lung Cancer Patients (LCP) were analyzed with a high sensitivity microcalorimeter VP-DSC (MicroCal – Malvern Panalytical). The data were processed in Origin 7.0 software. The plasma thermograms were analyzed through a multiparametric method developed by our research group. Statistical models allowed classifying the subjects according their serum thermograms.
Results
115 LCP subjects (average age 64.6±8.7, 83.0% men) with broad stage distribution (II: 5%, III: 26%; IV: 69%), smoking status (64% smoking, 7% non-smoking), histology distribution (37% adenocarcinoma, 29% squamous, 30% small cell) were compared to 119 HC subjects homogeneously distributed from a blood bank. TLB parameters obtained showed statistical differences between HC and LCP groups. Different statistical models were applied in order to establish the optimal TLB output, which is able to classify subjects according to their TLB thermogram: 92% success rate, 90% specificity, and 94% sensitivity (i.e., diagnostic odds ratio of 140).
Conclusions
High positive association between clinical groups and TLB multiparametric model offers advantages over current diagnosis techniques (LDCT imaging), providing a powerful diagnostic approach with a minimally-invasive, low-risk, low-cost clinical test for LCP. Future promising applications, such as screening programs, could be developed from TLB.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Instituto Carlos III (Spain).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5544 - Evaluation of a radiomic signature of CD8 cells in patients treated with immunotherapy-radiotherapy in three clinical trials.
Presenter: Roger Sun
Session: Poster Display session 3
Resources:
Abstract
1117 - Biomarkers predictive of overall survival in advanced cancer patients treated with a peptide-based cancer vaccine.
Presenter: Shigetaka Suekane
Session: Poster Display session 3
Resources:
Abstract
1922 - Expression of PD-L1 in plasma exosomes of NSCLC patients and its associations with PD-L1 expression of corresponding tumor tissues
Presenter: Shaorong Yu
Session: Poster Display session 3
Resources:
Abstract
5495 - Patient’s perspective on digital biomarkers in advanced urologic malignancies
Presenter: Severin Rodler
Session: Poster Display session 3
Resources:
Abstract
3166 - A comprehensive Pan-cancer study of FGFR Aberrations in Chinese cancer patients
Presenter: Yang Gao
Session: Poster Display session 3
Resources:
Abstract
3277 - A Systemic Inflammation Response Index (SIRI) correlates with survival and could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer (PC)
Presenter: Vilma Pacheco-Barcia
Session: Poster Display session 3
Resources:
Abstract
2680 - Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced Non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel)
Presenter: Alberto Pavan
Session: Poster Display session 3
Resources:
Abstract
4066 - Breast cancer in young women of Kazakh population depending on germline mutations: results of next-generation sequencing
Presenter: Dilyara Kaidarova
Session: Poster Display session 3
Resources:
Abstract
5514 - Discovery of an ImmunoTranscriptomics signature in blood for early colorectal cancer detection
Presenter: Paolo Angelino
Session: Poster Display session 3
Resources:
Abstract
1595 - Serum Netrin-1 as a Biomarker for Colorectal Cancer Detection
Presenter: Jinzhou Zhu
Session: Poster Display session 3
Resources:
Abstract